Comparative Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Retrospective Study

    July 2026 in “ Dermatology and Therapy ”
    Francesco D’Oria, S. Di Giulio, Luciano Ibba … Mario Valenti
    Studysummary In this retrospective study, baricitinib and ritlecitinib showed similar effectiveness and safety over 52 weeks for treating severe alopecia areata, with non-severe adverse events more common for baricitinib, driven by weight gain.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 25

    1. Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: Three-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies American Journal of Clinical Dermatology · 2026
    2. Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study American Journal of Clinical Dermatology · 2026
    3. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase 1/2 Inhibitor, in Adults with Alopecia Areata: Results from the THRIVE-AA2 Phase 3, Randomized, Double-Blind, Controlled Trial Journal of the American Academy of Dermatology · 2025
    4. Alopecia Areata Nature Reviews Disease Primers · 2025
    5. Alopecia Areata: A Comprehensive Review of Clinical, Immunologic, and Genetic Perspectives Discover Immunity. · 2025
    6. Immune Therapies for Alopecia Areata: Evidence and New Perspectives Expert Review of Clinical Immunology · 2025
    7. Effectiveness and Safety of Baricitinib in Severe Alopecia Areata: 48-Week Results Journal of the European Academy of Dermatology and Venereology · 2025
    8. Safety of Oral JAK Inhibitors in Treating Alopecia Areata: A Systematic Review and Network Meta-Analysis Frontiers in Pharmacology · 2025
    9. Strong Efficacy of Ritlecitinib 50 mg and Baricitinib 4 mg in Alopecia Areata, but Further Research Needed to Establish Superiority Journal of the European Academy of Dermatology and Venereology · 2025
    10. Alopecia Areata: Pathogenesis, Diagnosis, And Therapies MedComm · 2025
    11. Global Burden of Alopecia Areata and Associated Diseases: A Trend Analysis From 1990 to 2021 PubMed · 2025
    12. Baricitinib for the Treatment of Severe Alopecia Areata: Results from a 52-Week Multicenter Retrospective Real-World Study Journal of Dermatological Treatment · 2025
    13. Systematic Review and Indirect Treatment Comparisons of Ritlecitinib Against Baricitinib in Alopecia Areata Journal of the European Academy of Dermatology and Venereology · 2024
    14. Sustained Hair Regrowth With Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Trial Journal of the American Academy of Dermatology · 2024
    15. Long-Term Efficacy of Baricitinib in Alopecia Areata: 3-Year Results from BRAVE-AA1 and BRAVE-AA2 Journal of the American Academy of Dermatology · 2024
    16. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program American journal of clinical dermatology · 2024
    17. Inhibition of T-Cell Activity in Alopecia Areata: Recent Developments and New Directions Frontiers in immunology · 2023
    18. Effectiveness and Safety of Baricitinib in Patients With Severe Alopecia Areata: A 36-Week Multicenter Real-World Experience Journal of Dermatological Treatment · 2023
    19. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    20. Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2023
    21. Integrated Safety Analysis of Baricitinib in Adults With Severe Alopecia Areata From Two Randomized Clinical Trials British journal of dermatology/British journal of dermatology, Supplement · 2022
    22. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    23. New and Emerging Therapies for Alopecia Areata Drugs · 2020
    24. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    25. Alopecia Areata: An Autoimmune Disease Causing Hair Loss The New England Journal of Medicine · 2012